Marigolds AI

Access Map

Datroway

datopotamab deruxtecan-dlnk

HR+/HER2- mBC · 2L+ · TROP2 ADC
Medical benefit · J9011
Daiichi Sankyo / AstraZeneca

1 of 4 · The Soft Restriction

The policy is narrower than the label.

The Soft Restriction › The Payer Landscape › The Workspace › The Resolution

Datroway · HR+/HER2- mBC · US Medical-Benefit Access

Two forces are quietly narrowing who gets Datroway.

The FDA label is broad: all HER2-negative disease (HER2 IHC 0, 1+, 2+/ISH-) after prior endocrine therapy and chemotherapy, with no step-therapy and no prior-ADC condition. Two forces are narrowing it. One: TROPION-Breast01 enrolled before Enhertu became standard in HER2-low disease, so there is little trial evidence for the now-common Enhertu-then-Datroway sequence. Two: payer medical policies are adding conditions the label never set — a step-through-Enhertu requirement and an exclusion of prior TROP2 or topoisomerase-I therapy. The friction lands on on-label patients, concentrated exactly where treatment has moved.

Live · Not a crisis today. A pattern worth instrumenting before the ADC field crowds and the rules harden.

① The label allows

HR+, HER2-negative (HER2 IHC 0, 1+, 2+/ISH-) after prior endocrine therapy and chemotherapy. No step-through. No prior-ADC exclusion.

→ Broadly eligible

FDA label, 761394s000lbl

›

② The trial is narrower

TROPION-Breast01 enrolled before Enhertu became standard in HER2-low, with 1–2 prior chemo lines. Few post-Enhertu patients, so thin evidence for that now-common sequence.

→ Limited read-out for the sequence

TROPION-Breast01, JCO 2025

›

③ The policy is narrower still

A current payer policy adds two rules the label never set. Rule 1: step through Enhertu first (unless HER2 IHC 0). Rule 2: blocked after a prior TROP2 drug (Trodelvy) or topo-I therapy.

→ Narrower than approved

Prime Therapeutics IC-0814, Feb 2026

→

What we suggest: surface every policy that goes beyond the label, trace each clause to its source, and attach a lever — a label-alignment argument where a policy over-reads the indication, and a real-world-evidence watch on sequential-ADC activity for the evidence gap. We do not generate the missing trial evidence; that is your medical team. We make the gap visible and acted on before it hardens.

Rule 1 · step-through

must try Enhertu (the HER2 ADC) before Datroway, though the label sets no such condition

Prime IC-0814 · Feb 2026

Rule 2 · prior-ADC block

excluded after a prior TROP2 drug (Trodelvy) or topo-I therapy, also not in the label

Prime IC-0814 · Feb 2026

Why now · shared payload

Datroway, Trodelvy and the coming ADCs share a topo-I warhead, so prior-ADC rules will recur

FDA labels

Marigolds AI

Access Map

Datroway

datopotamab deruxtecan-dlnk

HR+/HER2- mBC · 2L+ · TROP2 ADC
Medical benefit · J9011
Daiichi Sankyo / AstraZeneca

2 of 4 · The Payer Landscape

Same label, different rules.

Soft Restriction › The Payer Landscape › The Workspace › The Resolution

Datroway · The payer landscape · Same label, different rules

One on-label drug, and payers land in very different places.

Datroway has one broad FDA label, but payer medical policies do not converge on it. They run from Medicaid and traditional Medicare plans that mirror the label, to commercial and Medicare Advantage plans that add hurdles the label never set. The management runs through a handful of recurring levers, scattered across hundreds of documents. Seeing the spread in one place is the access map. Two real, current policies on the same drug:

Louisiana Medicaid

At the label · CC-0279 · 2025

Approves on the FDA criteria only: HR+, HER2-negative (HER2 IHC 0/1+/2+ISH-), after prior endocrine therapy and chemotherapy. Denies only on safety (ILD history, active brain metastases). No step-through. No prior-ADC exclusion.

↳ Louisiana Medicaid medical drug criteria CC-0279, 2025

Prime Therapeutics

Beyond the label · IC-0814 · Feb 2026

Adds two conditions the label never set: step through Enhertu first (unless HER2 IHC 0), and no prior TROP2 (Trodelvy) or topo-I therapy. 6-month PA.

↳ Prime Therapeutics IC-0814, Feb 2026 · posted via Moda Health

Same drug, same approval, two different access experiences. The levers behind that spread:

Product preferencing

Steer to a preferred ADC before Datroway. Prime: step through Enhertu first.

Cross-resistance exclusion

Block after a prior same-class drug. Prime: no prior TROP2 (Trodelvy) or topo-I therapy.

Compendium-aligned

Defer to the FDA label and NCCN, no extra hurdle. Louisiana Medicaid, traditional Medicare.

Site-of-care / white-bagging

Force the infusion to a lower-cost site or a mandated specialty pharmacy. Standard lever for high-cost infusions, confirm per payer.

Pathway-vendor delegation

Many plans carve prior auth out to a few specialty vendors (Carelon, Evolent / New Century, OncoHealth). Their pathways can be stricter than the posted policy and are not public, so a handful of vendors quietly gate a large share of lives. The policy you can read may not be the one deciding the case.

The bottom line: both policies above are public, and we diff every posted policy against the label for you. The levers that are not posted — pathway-vendor rules, self-insured carve-outs, site-of-care mandates, Medicare Advantage internals — are the layer your account intelligence fills. That is the substance of the design partnership.

Marigolds AI

Access Map

Datroway

datopotamab deruxtecan-dlnk

HR+/HER2- mBC · 2L+ · TROP2 ADC
Medical benefit · J9011
Daiichi Sankyo / AstraZeneca

3 of 4 · The Workspace

Every gap. Every lever. Tracked.

Soft Restriction › The Payer Landscape › The Workspace › The Resolution

Gap → Lever → Owner → Tracked over time

A gap is not a finding. It is something you act on.

Each gap becomes a card: the claim, the diff, a recommended lever, an owner, and a status that moves over time. Here is the step-through gap from screen 1 as a worked card.

Step-through Enhertu requirement

Owner · Nat'l AccountsStatus · Confirmed · 1 policy, scanning

The claim

Datroway is on-label after prior endocrine therapy and chemotherapy. The label does not require prior Enhertu or any ADC sequence.

The gap

A live policy requires step-through Enhertu and excludes prior TROP2/topo-I therapy, both beyond the label. The IHC 0 carve-out shows the line is drawn on trial evidence.

Recommended lever: label-alignment dossier for the step-through (the requirement exceeds the indication), plus a real-world-evidence watch on sequential-ADC activity, which is the data that would let you challenge the prior-ADC exclusion. Not an NCCN-change claim — that runs through your medical team, which we flag but do not own.

Ask it anything grounded in the sourced docs

Marigolds · Datroway / HR+ HER2- mBC

Feed it your evidence · it compounds

✓FDA label · Datroway HR+/HER2-

✓TROPION-Breast01 protocol + JCO

✓NCCN compendium reference

✓Prime IC-0814 + other public policies

+Your field denial / appeal logs

+Pathway-vendor + self-insured criteria

The public foundation is live. Your account-level and self-insured detail is the layer that turns the worked example into your map.

Why this is not Policy Reporter, and not a Dedham scrub

Policy Reporter

Alerts

Tells you the policy text changed. It does not tell you the change is narrower than the label, or hand you the lever.

Dedham Group

Consulting

Scrubs policies once, by hand. Valuable but episodic. Not a living, structured, trackable system your team runs daily.

Marigolds AI

Access intelligence

Policy + clinical provenance + lever + tracking, in one workspace, re-checked as the evidence moves.

Marigolds AI

Access Map

Datroway

datopotamab deruxtecan-dlnk

HR+/HER2- mBC · 2L+ · TROP2 ADC
Medical benefit · J9011
Daiichi Sankyo / AstraZeneca

4 of 4 · The Resolution

How the restrictions come down.

Soft Restriction › The Payer Landscape › The Workspace › The Resolution

From problem to resolution · How we would work together

What it takes to actually remove a soft restriction.

Each clause that goes beyond the label comes down a different way. The work is to put the right lever on the right gap, give it an owner, and track whether it moved. Here are the two levers for the two rules from screen 1, what we would need from you, and how the partnership runs.

Lever A · act now

Label-alignment

For Rule 1 and any clause that over-reads the label (the step-through). Your account team shows the payer that the policy requires what the FDA label does not. No new evidence needed.

Owner: National Accounts + Field Reimbursement.
We provide: the sourced label-vs-policy diff, and we track the response.

Lever B · build

Evidence to NCCN

For Rule 2, the prior-ADC exclusion, which rests on a cross-resistance assumption. Real-world evidence that Datroway works after a prior ADC, argued to NCCN. When the compendium moves, payers follow.

Owner: Medical Affairs + HEOR.
We provide: the RWE and NCCN watch, and we flag the moment a restriction becomes challengeable.

What we would need from you to make it real

Field reality

Your denial and appeal logs, so we see where the restrictions actually bite, not just where they are written.

Delegated criteria

The pathway-vendor rules you encounter (Carelon, Evolent, OncoHealth) and self-insured carve-outs.

Your priorities

The handful of payers that drive most of your book, and which indication to anchor on first.

How the partnership runs

1

Map

Stand up the gap map for Datroway HR+/HER2- on the public foundation. Weeks, not months.

2

Monitor

Add your data, watch policy, NCCN, and RWE, and flag when a clause hardens or a restriction becomes challengeable.

3

Mobilize

Route each lever to its owner, track what moved the needle, and extend across TNBC and NSCLC as their policies lag each launch.

Where I want your input

Is the step-through what your field team sees, or are prior-ADC denials the live issue?

Which payers or pathway vendors have you already seen go beyond the label?

HR+/HER2- first, or would TNBC or NSCLC be more useful?